FDA Approves Seegene USA’s Multi-Plex PCR Test for Simultaneous Detection of Four Viruses

The U.S. Food and Drug Administration (FDA) has granted 510(k) clearance to Seegene USA for its Allplex™ SARS-CoV-2/FluA/FluB/RSV Assay, a multiplex real-time polymerase chain reaction (PCR) diagnostic test. This molecular diagnostic tool is designed to detect and differentiate four respiratory viruses—SARS-CoV-2, Influenza A, Influenza B, and Respiratory Syncytial Virus (RSV)—from a single patient specimen, providing a comprehensive diagnostic profile within a single clinical workflow.

Key Clinical Takeaways:

• The FDA-cleared assay utilizes multiplex PCR technology to simultaneously identify genetic markers for SARS-CoV-2, Influenza A, Influenza B, and RSV.
• By consolidating four viral targets into one test, the system aims to reduce the time required for differential diagnosis in patients presenting with overlapping respiratory symptoms.
• Clinical laboratories and diagnostic centers may now integrate this high-throughput platform to improve testing efficiency during seasonal respiratory disease surges.

The clinical challenge of distinguishing between these four pathogens lies in their overlapping symptomatic presentation, which often includes fever, cough, and fatigue. In a clinical setting, relying on single-target tests can delay appropriate therapeutic intervention. The integration of multiplex diagnostics into the standard of care is intended to mitigate the risk of diagnostic delay, particularly in immunocompromised populations where early viral identification dictates the initiation of antiviral therapy, such as oseltamivir for influenza or specific monoclonal antibodies for high-risk RSV cases.

The development of this assay, spearheaded by Seegene Inc., follows the company’s broader strategic shift toward “syndromic testing” models. According to technical documentation provided by the manufacturer, the assay utilizes the company’s proprietary AI-based assay design platform, which allows for the simultaneous amplification and detection of multiple viral RNA targets. This technological approach is validated by the clinical necessity to distinguish between pathogens that require vastly different clinical management protocols.

From an epidemiological perspective, the utility of such multiplex platforms is substantial. “The ability to rapidly triage patients based on specific viral etiology is the cornerstone of modern respiratory infection management,” notes Dr. Julian H. Thorne, a specialist in infectious disease diagnostics. “When clinicians can definitively rule out or confirm these four viruses in one pass, they significantly reduce the administrative and clinical burden on emergency departments and urgent care facilities.”

For healthcare institutions looking to refine their diagnostic capabilities, the transition to high-complexity, multiplexed PCR requires strict adherence to Laboratory Developed Test (LDT) regulations and quality control standards. Hospitals and diagnostic facilities should assess their current molecular infrastructure to ensure compatibility with standardized high-throughput PCR instrumentation. For those managing patient populations with high rates of respiratory morbidity, consulting with a [Board-Certified Clinical Pathologist or Diagnostic Compliance Specialist] can facilitate the necessary validation studies required to bring this technology online in a clinical environment.

The regulatory clearance of this assay by the FDA underscores a shift toward more efficient diagnostic workflows in the post-pandemic era. As public health agencies like the CDC continue to monitor the circulation of respiratory viruses, the demand for molecular assays that provide rapid, accurate, and multi-target results remains high. Institutions currently navigating the procurement of new diagnostic systems or auditing their existing supply chain for respiratory testing reagents are encouraged to engage with [Healthcare Procurement and Laboratory Infrastructure Services] to ensure that their diagnostic output aligns with current clinical guidelines and peak seasonal demand.

The future trajectory of diagnostic medicine is clearly trending toward comprehensive panels that minimize the need for sequential testing. By shortening the interval between patient presentation and definitive diagnosis, the healthcare system can optimize the use of antiviral stockpiles and reduce unnecessary antibiotic prescribing. As clinical research continues to evaluate the efficacy of these multiplex systems in longitudinal studies, the focus remains on ensuring that these tools are integrated into a robust, evidence-based diagnostic framework.

For providers seeking to implement these systems, the next steps involve a comprehensive review of equipment compatibility and staff training protocols. Ensuring that clinical staff are proficient in the interpretation of multi-target PCR readouts is essential for maintaining the high sensitivity and specificity standards required for clinical decision-making. Those looking to modernize their facility’s response to respiratory illness should consider reaching out to [Accredited Molecular Diagnostic Laboratories] for collaborative support in establishing these new testing benchmarks.

Disclaimer: The information provided in this article is for educational and scientific communication purposes only and does not constitute medical advice. Always consult with a qualified healthcare provider regarding any medical condition, diagnosis, or treatment plan.